Physician profile
Alexandra Groot
NPI 1629670427
$1,385.91
in general payments reported to CMS, 2019-2025
13 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $933 · 2023: $159 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $525.32 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $274.86 | 2022-2025 | Caplyta |
| Lundbeck LLC | $116.24 | 2022-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $102.23 | 2022-2025 | Abilify Maintena, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $75.82 | 2022-2025 | Trintellix |
| Corium, LLC | $60.43 | 2022-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $54.29 | 2022-2023 | Qelbree |
| Alkermes, INC. | $47.77 | 2022-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $34.46 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $32.45 | 2022 | |
| Neurocrine Biosciences, INC. | $22.82 | 2022 | |
| Tris Pharma INC | $21.88 | 2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $17.34 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Groot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.